CME Information

Activity Title	Addressing the Barriers to Effective Pain Management and Issues of Opioid Misuse and Abuse Virtual Mentorship Training Program
Topic	Pain Management
Target Audience	Pain Management Faculty Presenters
Accreditation Type	CME
Release Date	September 2009
Expiration Date	June 30, 2010
Estimated Time to Complete Activity	90 minutes

LEARNING OBJECTIVES

Upon completion of the activity, participants should be able to:

• Identify the negative impact of persistent pain on health and quality of life, current methods to assess pain levels, appropriate use of opioid medications, and documentation required for compliance with regulatory policies
• Integrate appropriate risk assessment strategies for patient abuse, misuse, and diversion among opioid therapies into an overall management approach for acute and chronic pain
• Describe the specific elements of new abuse deterrent technologies associated with opioid therapy and assess their implications for clinical practice

CONTENT DEVELOPMENT FACULTY

Lynn R. Webster, MD, FACPM, FASAM (Chairperson)
Medical Director, Lifetree Clinical Research and Pain Clinic
Chief of Anesthesiology
Health South Salt Lake Surgical Center
Salt Lake City, Utah

Perry G. Fine, MD
Professor, Department of Anesthesiology
Pain Research Center
University of Utah School of Medicine
Salt Lake City, Utah

Scott M. Fishman, MD
Chief, Division of Pain Medicine
Professor of Anesthesiology and Pain Medicine
University of California, Davis
Davis, California

ACTIVITY FACULTY

Lynn R. Webster, MD, FACPM, FASAM (Chairperson)
Medical Director, Lifetree Clinical Research and Pain Clinic
Chief of Anesthesiology
Health South Salt Lake Surgical Center
Salt Lake City, Utah

SPONSOR

This activity is sponsored by The France Foundation.

TARGET AUDIENCE

This activity is intended for health care professionals who have a direct role in the management of acute and/or chronic pain, including Rheumatologists, Neurologists/Neurosurgeons, Urologists, Oncologists, General Surgeons, Orthopedic Surgeons, Emergency Medicine Specialists, Internists/Family Physicians, OB/GYNs, Anesthesiologists, and Pain Management Physicians.

STATEMENT OF NEED

This activity has been planned in accordance with the need to provide health care professionals with an interactive continuing medical education activity that addresses the benefits and risks of opioid therapy, assessment strategies, abuse deterrent technologies (ADTs), and required documentation for compliance of regulatory policies in order to address challenges related to the increase in prescription drug abuse and the undertreatment of pain.

ACCREDITATION STATEMENT

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

Physicians
The France Foundation designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits&trade. Physicians should only claim credit commensurate with the extent of their participation in the activity.

RESOLUTION OF CONFLICTS OF INTEREST

In accordance with the ACCME Standards for Commercial Support of CME, The France Foundation will implement mechanisms, prior to the planning and implementation of this CME activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME activity.

DISCLOSURE

It is the policy of The France Foundation to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty, activity planners, and staff involved in the development of this activity have disclosed any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. The France Foundation has identified and resolved any and all conflicts of interest prior to the release of this activity.

Activity Staff Disclosures

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

CONTENT DEVELOPMENT FACULTY DISCLOSURE

The following faculty have indicated they have relationships with industry to disclose relative to the content of this CME activity:

• Lynn R. Webster, MD, FACPM, FASAM, has received grants/research support from Arcion, Advanced Bionic, Pfizer, Cephalon, CoMentis, Forest, Hisamitsu, Hoffman LaRoche, King Pharmaceuticals, Medtronic, Merck, Myriad, Nektar, NeurogesX, XenoPort and Wyeth. He has received honoraria from Ameritox, Cephalon, Medtronic, King Pharmaceuticals, Nektar, Nervo, Neuromed, and Purdue.
• Perry G. Fine, MD, serves as consultant for Cephalon, King Pharmaceuticals, Neuroadjuvants, and OrthoMcNeil/Pricara. He has received honorarium from Forest and acts as medical expert on behalf of Janssen & Alza.
• Scott M. Fishman, MD, has received grants/research support and has served as consultant and speakers bureaus for Elan Company, Endo Pharmaceuticals, Janssen Medical Affairs, Merck, Pfizer, and Purdue. He as also served as consultant for Cephalon, and Eli Lilly and Company.

ACTIVITY FACULTY DISCLOSURE

The following faculty have indicated they have relationships with industry to disclose relative to the content of this CME activity:

• Lynn R. Webster, MD, FACPM, FASAM, has received grants/research support from Arcion, Advanced Bionic, Pfizer, Cephalon, CoMentis, Forest, Hisamitsu, Hoffman LaRoche, King Pharmaceuticals, Medtronic, Merck, Myriad, Nektar, NeurogesX, XenoPort and Wyeth. He has received honoraria from Ameritox, Cephalon, Medtronic, King Pharmaceuticals, Nektar, Nervo, Neuromed, and Purdue.

UNAPPROVED USE DISCLOSURE

The France Foundation requires CME faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

COMMERCIAL SUPPORT ACKNOWLEDGMENT

This activity is supported by an educational grant from King Pharmaceuticals.

DISCLAIMER

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and King Pharmaceuticals assume no liability for the information herein.

COPYRIGHT INFORMATION

Copyright © 2010 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

• The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
• Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.

PRIVACY POLICY

The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.

Additional information regarding The France Foundation's Privacy Policy can be viewed at http://www.francefoundation.com/privacy.

CONTACT INFORMATION

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.